DECEMBER 2022

• Drug Sensitivity of Currently Circulating Mpox Viruses
  NEJM, December 28, 2022
• Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
  Nature Communications, December 27, 2022
• Clonal replacement sustains long-lived germinal centers primed by respiratory viruses
  Cell, December 23, 2022
• Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
  Science Immunology, December 23, 2022
• Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study
  Lancet infectious disease, December 22, 2022
• Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
  NEJM December 21, 2022
• Persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium
  Science translational medicine, December 21, 2022
• Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children
  Science, December 20, 2022
• Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
  Nature reviews immunology, December 20, 2022
• Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status
  Clinical Infectious Diseases, December 15, 2022
• Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
  Science Immunology, December 16, 2022
• A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines
  NEJM, December 15, 2022
• Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
  Cell, December 13, 2022

• An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2
  Cell host and microbe, December 8, 2022
• Monkeypox: potential vaccine development strategies
  Trends in Pharmacological Sciences, December 8, 2022
• Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
  The Lancet Microbe, December 6, 2022
• FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
  Nature, December 5, 2022
• Defining antigen targets to dissect vaccinia virus and mpox virus-specific T cell responses in humans
  Cell Host & Microbe, December 3, 2022
• Gradual emergence followed by exponential spread of the SARS-CoV-2 Omicron variant in Africa
  Science, December 2, 2022
• Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
  NEJM, December 1, 2022

NOVEMBER 2022

• Tecovirimat for Monkeypox in Central African Republic under Expanded Access
  NEJM, November 30, 2022
• High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
  Nature communications, November 28, 2022
• Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
  Science, November 27, 2022
• Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity
  Nature communications, November 25, 2022
• A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins
  Nature chemical biology, November 21, 2022
• Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
  The Lancet Infectious Diseases, November 18, 2022
• Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
  Science Immunology, November 18, 2022
• Monkeypox
  Lancet, November 17, 2022
• Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
  Science Immunology, November 15, 2022
• Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial
  Nature Microbiology, November 14, 2022
• Host genetic variability and determinants of severe COVID-19
  Trends in Genetics, November 12, 2022
• Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in macaques
  Cell, November 10, 2022
• Acute and postacute sequelae associated with SARS-CoV-2 reinfection
  Nature Medicine, November 10, 2022
• Acute and postacute sequelae associated with SARS-CoV-2 reinfection
  Nature Medicine, November 10, 2022
• Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
  Nature, November 9, 2022
• Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection
  Nature Communications, November 7, 2022
• Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations
  Nature Microbiology, November 7, 2022
• Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
  J Exp Med, November 7, 2022
• Shared genetic influences between blood analyte levels and risk of severe COVID-19
  Cell Reports, November 6, 2022
• Monkeypox: epidemiology, pathogenesis, treatment and prevention
  Nature, Signal Transduction and Targeted Therapy, November 2, 2022
• Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination
  Science Immunology, November 1, 2022
• Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
  Nature Communications, November 1, 2022

• Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2
  EbioMedicine, November 1, 2022

OCTOBER 2022

• Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
  Nature Communications, October 29, 2022
• Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
  Science, October 27, 2022
• Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
  Cell Reports, October 26, 2022
• Pre-infection antiviral innate immunity contributes to sex differences in SARS-CoV-2 infection
  Cell systems, October 26, 2022
• Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
  Cell Reports, October 26, 2022
• Pre-infection antiviral innate immunity contributes to sex differences in SARS-CoV-2 infection
  Cell systems, October 26, 2022
• Monkeypox
  NEJM, October 26, 2022
• Sterilizing immunity: Understanding COVID-19
  Immunity, October 23 2022
• Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
  Nature Communications, October 23, 2022
• Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
  Science, October 20, 2022
• Multiple lineages of monkeypox virus detected in the United States, 2021–2022
  Science, October 20, 2022
• Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
  Nature Medicine, October 2022
• Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
  NEJM, October 19, 2022
• Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
  Lancet, October 15, 2022
• Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark
  Lancet, October 18, 2022
• Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  Nature Medicine, Oct 18, 2022
• Retrospective detection of monkeypox virus in the testes of nonhuman primate survivors
  Nature Microbiology, Oct 17, 2022
• Therapeutic advances in COVID-19
  Nature Reviews Nephrology, October 17, 2022
• SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
  Nature Communications, October 17, 2022
• Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
  NEJM, October 12, 2022
• Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
  NEJM, October 12, 2022
• Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses
  PNAS, October 10, 2022
• Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
  eBioMedicine, October 10, 2022
• Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
  Cell Host & Microbe, October 9, 2022
• Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals
  Nature Scientific Reports, October 7, 2022
• The Neurobiology of Long COVID
  Neuron, Oct 6, 2022
• A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
  Cell Reports, October 5, 2022
• Long-term neurological sequelae of SARS-CoV-2 infection
  Nature Medicine, October 3, 2022
• Monkeypox trial to begin in DR Congo
  Lancet Infectious Diseases, October 1, 2022

SEPTEMBER 2022

• Lingering cardiac involvement in previously well people after mild COVID-19
  Nature Medicine, September 26 2022
• A distinct symptom pattern emerges for COVID-19 long-haul: a nationwide study
  Nature, September 23, 2022
• Monkeypox: A public health emergency in Brazil
  Lancet Regional Health, Sep 23, 2022
• SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages
  Science translational medicine, Sep 22, 2022
• Monkeypox: Where are the racial disparities?
  Lancet regional Health, Sep 22, 2022
• Monkeypox transmission—what we know so far
  Lancet Respiratory medicine, Sep 22, 2022
• SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression
  Science, September 21, 2022
• SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression
  Science, September 21, 2022
• Differential proinflammatory activities of Spike proteins of SARS-CoV-2 variants of concern
  Science Direct, September 16, 2022
• A Bivalent Omicron-Containing Booster Vaccine against Covid-19
  NEJM, September 16, 2022
• Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
  NEJM, September 14, 2022
• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
  Science Translational Medicine, September 14, 2022
• Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants including BA.4 and BA.5
  Cell, September 13, 2022
• Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19
  Science, September 9, 2022
• Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors
  Nature Chemical biology, September 8, 2022
• Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
  NEJM, September 7, 2022
• Dissecting the role of the human microbiome in COVID-19 via metagenome-assembled genomes
  Nature Communications, September 6, 2022

• Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
  The Lancet Respiratory Medicine, September 5, 2022
• Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study
  The Lancet Global Health, September 1, 2022

AUGUST 2022

• SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis
  PNAS, August 30, 2022
• A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
  Nature Communications, August 30, 2022
• Spike Protein-independent Attenuation of SARS-CoV-2 Omicron Variant in Laboratory Mice
  Cell Reports, August 28, 2022
• Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2
  Cell Reports Medicine, August 28, 2022
• Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
  NEJM, August 18, 2022
• Asymptomatic Infection? Another Reason to Consider Monkeypox a Disease of Public Health Concern
  Annals of Internal Medicine, August 16, 2022
• Multiple BCG vaccinations for prevention of COVID-19 and other infectious diseases in Type 1 diabetes
  Cell Reports Medicine, August 15, 2022
• Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
  Cell Reports Medicine, August 15, 2022
• Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
  Nature Communications, August 13, 2022
• An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion
  Science Immunology, August 11, 2022
• The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination
  Immunity, August 11, 2022
• Update on the Monkeypox Outbreak
  JAMA Network, August 11, 2022
• Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
  NEJM, August 11, 2022
• Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2
  Molecular Therapy, August 9, 2022
• CD8 T Cells Contribute to Vaccine Protection Against SARS-CoV-2 in Macaques
  Science Immunology, Aug 9, 2022
• Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study
  The Lancet, August 6, 2022
• Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
  Cell Reports Medicine, August 4, 2022
• Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron
  Cell, Host & Microbe August 4, 2022
• A first update on mapping the human genetic architecture of COVID-19
  Nature, August 3, 2022
• Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations
  NEJM, August 3, 2022
• Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel
  JAMA Network, August 2, 2022

JULY 2022

• Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera
  eBioMedicine July 29, 2022
• Profiling post-COVID syndrome across different variants of SARS-CoV-2
  MedRxiv, July 31, 2022
• Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19
  Nature. July 28, 2022
• An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
  Science Immunology, July 29, 2022
• The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic
  Science, July 26, 2022
• The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
  Science, July 26, 2022
• Symptoms and risk factors for long COVID in non-hospitalized adults
  Nature Medicine, July 25, 2022
• SARS-CoV-2 epitope–specific CD4+ memory T cell responses across COVID-19 disease severity and antibody durability
  Science Immunology, July 22, 2022
• Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
  Science, July 19, 2022
• Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
  The Lancet Infectious Diseases, July 15, 2022
• Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants
  NEJM, July 14, 2022
• Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants
  iScience, July 14, 2022
• Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection
  JAMA Network Open July 13, 2022
• Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants
  MedRxiv, July 12, 2022
• Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
  MedRxiv, July 12, 2022
• Monoclonals for patients hospitalised with COVID-19
  The Lancet Respiratory Medicine, July 8, 2022
• Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera
  Nature Communication, July 7, 2022
• SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
  Science Translational Medicine, July 7, 2022
• Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
  NEJM, July 6, 2022
• SARS-CoV-2 3CLpro mutations confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system
  Biorxiv, July 4, 2022
• Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccine
  Medrxiv, July 4, 2022
• Global monkeypox outbreak
  Lancet Infectious Diseases July 1, 2022

JUNE 2022

• Why does viral RNA sometimes persist after recovery from acute infections? – PMC (nih.gov)
  PLoS Biology, June 2022
  GVN Center Director Diane Griffin (Johns Hopkins Bloomberg School of Public Health
• IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
  Science Immunology, June 30, 2022
• A broad and potent neutralization epitope in SARS-related coronaviruses
  PNAS June 29, 2022
• Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution
  Science, June 28, 2022
• Persistent 129Xe MRI Pulmonary and CT Vascular Abnormalities in Symptomatic Individuals with Post-Acute COVID-19 Syndrome
  Radiology, June 28, 2022
• A Bivalent Omicron-containing Booster Vaccine Against Covid-19
  MedRxiv, June 25, 2022
• Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
  eClinicalMedicine, June 25, 2022
• Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
  NEJM, June 22, 2022
• SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters
  Nature Communications, June 20, 2022
• Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant
  Cell Reports Medicine, June 19, 2022
• What SARS-CoV-2 does to our brains
  Immunity, June 19, 2022
• BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
  Nature, June 17, 2022
• Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
  NEJM, June 17, 2022
• Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2
  The Lancet, June 17, 2022
• Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
  JEM, June 15, 2022
• Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
  Science, June 14, 2022
• Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases
  The Lancet, June 11, 2022
• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
  The Lancet, June 11, 2022
• Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
  NEJM, June 9, 2022
• Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
  The Lancet Respiratory Medicine, June 9, 2022
• SARS-CoV-2 infection relaxes peripheral B cell tolerance
  J Exp Med (2022) 219 (6): e20212553.
• Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
  Science Immunology, June 2, 2022

MAY 2022

• Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
  BMJ, May 2022
• Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study
  medRxiv, May 30, 2022
• Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results
  News Medical, May 24, 2022
• Genomic characterization of the recent monkeypox outbreak
  bioRxiv, June 3, 2022
• Mask wearing in community settings reduces SARS-CoV-2 transmission
  PNAS, May 31, 2022
• Long COVID after breakthrough SARS-CoV-2 infection
  Nature Medicine, May 25, 2022
• Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
  bioRxiv, May 23, 2022
• Impact of natural selection on global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection
  PNAS, May 17, 2022
• Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
  NEJM, May 18, 2022
• Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
  The Lancet eClinicalMedicine, May 12, 2022
• Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study
  The Lancet Respiratory Medicine, May 11, 2022
• Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
  NEJM, May 11, 2022
• SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
  Cell Host & Microbe, May 5, 2022
• Omicron infection enhances Delta antibody immunity in vaccinated persons
  Nature, May 6, 2022
• Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
  The Lancet, May 2, 2022
• Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
  Cell, May 4, 2022

APRIL 2022

• Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection
  JAMA, April 29, 2022
• An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
  Science Immunology, April 26, 2022
• LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
  Cell Reports, April 24, 2022
• Regional replacement of SARS-CoV-2 variant BA.1 with BA.2 as observed through wastewater surveillance
  medRxiv, April 22, 2022
• Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
  NEJM, April 20, 2022
• Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative
  JAMA, April 15, 2022
• Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
  Emerging Infectious Diseases, April 2022
• Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
  NEJM, April 13, 2022
• Persistent COVID-19 symptoms in a community study of 606,434 people in England
  Nature Communications, April 12, 2022
• Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2
  Nature Medicine, April 8, 2022
• Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
  NEJM, April 5, 2022
• Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US
  JAMA Pediatrics, April 1, 2022

MARCH 2022

• Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
  The Lancet Infectious Diseases, March 31, 2022
• Effect of Early Treatment with Ivermectin among Patients with Covid-19
  NEJM, March 30, 2022
• Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
  The Lancet Microbe, March 28, 2022
• SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses
  The Lancet, March 25, 2022
• Risks and burdens of incident diabetes in long COVID: a cohort study
  The Lancet Diabetes and Endocrinology, March 21, 2022
• Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees
  Emerging Infectious Diseases, March 15, 2022
• Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
  NEJM, March 16, 2022
• A broad and potent neutralization epitope in SARS-related coronaviruses
  BioRxiv, March 14, 2022
• Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study
  The Lancet Infectious Diseases, March 11, 2022
• Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
  NEJM, March 9, 2022
• SARS-CoV-2 is associated with changes in brain structure in UK Biobank
  Nature, March 7, 2022
• Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters
  bioRxiv, March 4, 2022
• Antibody evasion properties of SARS-CoV-2 Omicron sublineages
  Nature, March 3, 2022

FEBRUARY 2022

• Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
  MedRxiv, February 28, 2022
• Large-scale implementation of rapid antigen testing system for COVID-19 in workplaces
  Science Advances, February 25, 2022
• Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
  BioRxiv, February 15, 2022
• Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study
  The Lancet Child & Adolescent Health, February 18, 2022
• The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
  Nature Communications, February 15, 2022
• Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance
  MedRxiv, February 15, 2022
• Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
  CDC, February 11, 2022
• Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
  Nature, February 9, 2022
• Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study
  MedRxiv, February 7, 2022
• Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  Science Immunology, February 3, 2022
• Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals
  MedRxiv, February 2, 2022

JANUARY 2022

• Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households
  MedRxiv, January 30, 2022
• Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021
  MedRxiv, January 27, 2022
• Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVD-19 respiratory disease
  Cell Immunity, January 25, 2022
• Nasally-delivered interferon-{lambda} protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
  BioRxiv, January 24, 2022
• Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
  MedRxiv, January 23, 2022
• Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination
  MedRxiv, January 17, 2022
• Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant
  MedRxiv, January 16, 2022
• Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron
  MedRxiv, January 11, 2022
• Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children
  MedRxiv, January 10, 2022
• Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
  MedRxiv, January 8, 2022
• The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
  MedRxiv, January 3, 2022